Role of Enoxaparin in the Management of STEMI: An Indian Perspective

Abstract

Cardiovascular diseases are major causes of morbidity and mortality worldwide. Acute coronary syndrome is one of the main causes of hospital admissions. ST-elevation myocardial infarction is the severe dreaded ACS causing morbidity and mortality. Probably because of economic reasons, conventional heparin continues to be the main anticoagulant therapy in STEMI. Enoxaparin is safe and effective in the treatment of ST-elevation myocardial infarction. Various studies outline its efficacy and safety in STEMI. The benefits of enoxaparin outweigh the minor risk of hemorrhages noted with its use. The cost of therapy is high for an average Indian patient. The biosimilar enoxaparin needs to be studied well before it can be deemed equivalent to the original molecule.